Menu
No results found.
Weekly Share Price & Valuation Overview
BioArctic AB (publ)
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
- Growth + profitability: double-digit revenue and profit margins.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- ROE ≥15% reflects strong returns on shareholder equity.
- ROA ≥7% shows efficient use of assets.
- Revenue growth ≥10% indicates solid top-line momentum.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- SEK 21.09B
- Enterprise Value Operating value: market cap + total debt − cash.
- SEK 20.35B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- SEK 1.52B
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- SEK 1.48B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- SEK 939.30M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- SEK 17.17
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 10.17
- Shares Outstanding
- 74.13M
- Float Shares
- 53.14M
- Implied Shares Outstanding
- 88.53M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
83.31%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
61.91%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
97.61%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
59.44%
- ROA Strong Return on assets: net income ÷ total assets.
-
35.28%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
61.64%
- Revenue Growth Strong Year-over-year revenue growth.
-
42.51%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 5.21
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.03
- Total Cash Cash and equivalents.
- SEK 788.57M
- Total Debt Short + long-term interest-bearing debt.
- SEK 50.99M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- SEK -737.57M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.05
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- SEK -190.14M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- SEK -54.76M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-12.53%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-3.61%
- Cash Conversion (OpCF/EBITDA)
- -0.20
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.